DNA methylation epigenotype and clinical features of NRAS -mutation(+) colorectal cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DNA methylation epigenotype and clinical features of NRAS
-mutation(+) colorectal cancer
Authors
Keywords
-
Journal
Cancer Medicine
Volume 6, Issue 5, Pages 1023-1035
Publisher
Wiley
Online
2017-04-06
DOI
10.1002/cam4.1061
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- RASmutation is a prognostic biomarker in colorectal cancer patients with metastasectomy
- (2016) Hiroki Osumi et al. INTERNATIONAL JOURNAL OF CANCER
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
- (2015) Luisa Foltran et al. Future Oncology
- Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway
- (2015) Eiji Sakai et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic value ofKRASandBRAFmutations in curatively resected colorectal cancer
- (2015) Shigenori Kadowaki WORLD JOURNAL OF GASTROENTEROLOGY
- Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
- (2015) Jing Zhang et al. Scientific Reports
- Mutational analysis and clinical correlation of metastatic colorectal cancer
- (2014) Andrea L. Russo et al. CANCER
- Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer
- (2014) Marta Schirripa et al. INTERNATIONAL JOURNAL OF CANCER
- Methylation epigenotypes and genetic features in colorectal laterally spreading tumors
- (2014) Eiji Sakai et al. INTERNATIONAL JOURNAL OF CANCER
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
- (2014) Alfonso De Stefano WORLD JOURNAL OF GASTROENTEROLOGY
- The CIMP Phenotype inBRAFMutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort
- (2014) Winnie C. Fernando et al. Gastroenterology Research and Practice
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
- (2013) Yinchen Shen et al. PLoS One
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients
- (2012) Elisabeth Pérez-Ruiz et al. TUMOR BIOLOGY
- Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression
- (2012) Yufang Wang et al. Cancer Discovery
- Classification of Epstein-Barr Virus-Positive Gastric Cancers by Definition of DNA Methylation Epigenotypes
- (2011) K. Matsusaka et al. CANCER RESEARCH
- Genome-scale analysis of aberrant DNA methylation in colorectal cancer
- (2011) T. Hinoue et al. GENOME RESEARCH
- Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study
- (2010) Adam Naguib et al. BMC CANCER
- Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes
- (2010) Atsushi Kaneda et al. CANCER SCIENCE
- NRAS Mutations Are Rare in Colorectal Cancer
- (2010) Natsumi Irahara et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Colorectal cancer
- (2010) David Cunningham et al. LANCET
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Three DNA Methylation Epigenotypes in Human Colorectal Cancer
- (2009) K. Yagi et al. CLINICAL CANCER RESEARCH
- Isoform-specific ras functions in development and cancer
- (2009) Margaret P Quinlan et al. Future Oncology
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer
- (2009) Ken S. Lau et al. MOLECULES AND CELLS
- Genetic pathways to colorectal cancer
- (2009) Isabel A. Lea et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
- (2009) Bijay S. Jaiswal et al. PLoS One
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
- (2008) Kevin M Haigis et al. NATURE GENETICS
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More